Tirzepatide Switcher Guide

The evidence base in plain English

Tirzepatide is a dual GLP-1 + GIP agonist - a molecule that mimics two gut hormones (GLP-1 and GIP) at once instead of just one. Semaglutide is a GLP-1 agonist - it mimics only GLP-1. The dual mechanism appears to be what drives the larger weight loss in head-to-head studies.

The SURMOUNT-5 trial, published in NEJM in May 2025, is the first phase-3 head-to-head comparison. It randomized 751 adults with obesity (without diabetes) to maximum-tolerated tirzepatide (10 or 15mg) or maximum-tolerated semaglutide (1.7 or 2.4mg) for 72 weeks. Tirzepatide produced 20.2% mean weight loss versus 13.7% for semaglutide - a 6.5 percentage point absolute difference (Aronne et al. 2025, NEJM; PMID 40353578).

The earlier cross-trial benchmarks showed 22.5% mean weight loss for tirzepatide 15mg in SURMOUNT-1 versus 14.9% for semaglutide 2.4mg in STEP-1, but those were different populations and different protocols. SURMOUNT-5 is the head-to-head version of the same comparison.

For diabetes outcomes, SURPASS-2 compared tirzepatide to semaglutide 1mg in type 2 diabetes patients. Tirzepatide produced larger HbA1c reductions and larger weight loss across all three tested doses (5mg, 10mg, 15mg) (Frias et al. 2021, NEJM).

Honest framing: tirzepatide is the larger-effect molecule on average. It is not a guaranteed bigger result for every individual. About 30% of users in SURMOUNT-5 reached 25% or more weight loss on tirzepatide versus 16% on semaglutide - meaning the responder rate at high thresholds is roughly doubled, but most of the population sits in the 10 to 20% range on either drug.

Week 0: the doctor conversation

Three questions for the appointment:

• Is the switch worth it for my specific case? If you are at goal weight on semaglutide and tolerating it well, the switch may not be worth the side-effect reset. If you have stalled at the maximum semaglutide dose with weight to go, or if GI side effects on semaglutide are not improving, the switch carries a credible upside. Your provider should help you weigh that.
• What is the switching protocol? Most providers recommend taking your last semaglutide dose, waiting one week (the standard interval, since semaglutide is dosed weekly), then starting tirzepatide at 2.5mg the following week. This is not a no-washout switch - GI side effects can stack if you do not give the semaglutide time to clear (its half-life is roughly 7 days).
• Branded or compounded? The FDA declared tirzepatide off shortage in late 2024 and reaffirmed that status into 2025-2026. That means the legitimate compounding window has narrowed substantially. Some compounders still operate under specific patient-level exemptions; many do not. Ask your provider which legal framework their compounding pharmacy is operating under in 2026.

Week 1: sourcing in 2026

The legitimate paths in 2026:

• Insurance-covered branded Mounjaro or Zepbound. If your insurance covers Wegovy or Ozempic, it often covers Zepbound or Mounjaro (sometimes with prior authorization). Cost with coverage typically $25 to $100 per month copay. Eli Lilly's manufacturer copay program brings cost down further for eligible patients.
• Lilly Direct (cash pay). Eli Lilly's direct-to-patient program sells single-dose vials of Zepbound at fixed cash prices that are notably lower than retail pharmacy prices ($349 to $499 per month range as of mid-2025; check current pricing). This is the legitimate cash-pay path for branded tirzepatide.
• Telehealth with compounded tirzepatide. Narrower in 2026 than in 2024 due to the FDA shortage status change. Some providers continue to compound under patient-specific exemptions; the regulatory ground is shifting. Cost typically $300 to $500 per month when available.
• Skip: Research-peptide-vendor "tirzepatide" purchased without a prescription. The molecule sold there is not the same manufacturing context as Mounjaro or Zepbound. Quality varies wildly. No clinical trial covers that supply chain.

Weeks 2 onward: the switching protocol and titration

The standard switching sequence:

• Take your last semaglutide dose on its normal schedule. Wait 7 days (the standard inter-dose interval).
• Start tirzepatide at 2.5mg subQ once weekly at the end of that wait week. Yes, even if you were on a high semaglutide dose. Tirzepatide titration starts at 2.5mg regardless of your prior GLP-1 dose. This is per the FDA prescribing information for both Mounjaro and Zepbound (Zepbound Prescribing Information, 2025).
• Titrate up by 2.5mg every 4 weeks if tolerated, with provider approval at each step: 2.5 to 5 to 7.5 to 10 to 12.5 to 15mg. Maintenance doses approved for weight loss are 5, 10, or 15mg per the Zepbound label.
• Reassess at week 12 and week 24 for weight loss, GI tolerance, and metabolic markers. Most users hit their first major checkpoint at the 5 to 10mg range.
• Side-effect management. Nausea is the most common GI side effect on either drug. Compared to semaglutide, tirzepatide tends to produce slightly less GI discontinuation in head-to-head data (2.7% on tirzepatide vs 5.6% on semaglutide in SURMOUNT-5). Anti-nausea medication (ondansetron - brand name Zofran) for the first 1 to 2 weeks of each dose increase is the standard countermeasure.

What success looks like

By week 12 on tirzepatide (typically at the 7.5 or 10mg dose), users who switched from a stalled semaglutide protocol commonly see weight loss resume - typically 1 to 2 pounds per week through the first 12 weeks of titration. If you were stuck at a plateau on semaglutide 2.4mg, expect to break through that plateau by the time you reach tirzepatide 7.5 or 10mg.

By week 24, most users are at maintenance dose (5, 10, or 15mg) and the weight loss curve flattens. The total trajectory at 72 weeks looks like the SURMOUNT-1 and SURMOUNT-5 results: 20 to 22% mean body weight loss, with substantial individual variation.

If at week 12 your weight has not budged at all on tirzepatide, the switch did not buy you what you hoped. Have the follow-up conversation with your provider about whether to continue, escalate dose more aggressively, or look at non-pharmacological factors that might be holding the trajectory back.

What to skip

• "Stacking" semaglutide and tirzepatide simultaneously. Some forums recommend running both at low doses for a "synergy effect." There is no clinical evidence for that approach and substantial overlap in the receptor mechanism. Pick one.
• Skipping the 7-day washout. Semaglutide has a roughly 7-day half-life. Starting tirzepatide on top of substantial circulating semaglutide stacks GI side effects unnecessarily.
• Going straight to a high tirzepatide dose because you were on high semaglutide. Per the FDA label, every tirzepatide course starts at 2.5mg. The cross-titration shortcut is not what was studied.
• "Tirzepatide plus 4-peptide weight loss stack" from anti-aging clinics. Adding sermorelin, MOTS-c, AOD-9604, and other peptides on top of tirzepatide is not what the trial evidence supports. The stack is the clinic's revenue model. Single-molecule tirzepatide is the studied protocol.

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Broken down for normal humans.

Subscribe free